Looking back at the development history of HER2-targeted drugs, since trastuzumab was launched as the first HER2-targeted mAb in 1998, it has not only changed the treatment landscape for HER2-positive breast cancer patients but also promoted clinical transformation. This evidence concerns the gene ERBB2 and breast carcinoma.